Corporate
Another Woman on the Merz Pharma Board
The Merz Pharma Group in Frankfurt has appointed Dr. Anke Frankenberger, who has a doctorate in law, to the position of Chief Legal Counsel. On the Merz Pharma Board, she will be responsible for the company’s Legal and Patent Affairs.
“It is with great pleasure that we welcome such a renowned legal professional to our Board,” said Philip Burchard, the CEO of Merz. “In hiring Dr. Frankenberger, we have not only brought another gifted figure of international standing into our company; we have also fulfilled our goal of appointing more women to leadership positions.”
Dr. Frankenberger has years of international experience as an in-house corporate lawyer. In her most recent position, she was the General Counsel and Chief Compliance Officer at Styrolution in Frankfurt, a leading global provider of styrenics, wholly owned by INEOS. She previously performed the same function at Nordex, the Hamburg-based wind turbine manufacturer. At an earlier stage in her career, she held a job at the specialty chemicals company Evonik Degussa that involved stays in China and the U.S.
Currently, the Merz Pharma Board comprises ten men and two women.
Merz is a privately held pharmaceutical company based in Frankfurt, Germany, with 33 subsidiaries in European countries, North America, Latin America, and Asia-Pacific. The company is active in research, development, and distribution of innovative products in the areas of aesthetic medicine, dermatology and neurologically induced movement disorders.
In the Aesthetics segment Merz offers a balanced portfolio of products for minimally invasive treatments. With the dermal fillers Radiesse, Belotero, and Glytone and the botulinum neurotoxin Bocouture/Xeomin as well as the Neocutis line of anti-aging products, the company is a major player in the global aesthetics market. The company‘s offerings were supplemented by ultrasound-technology after the acquisition of Ulthera in mid 2014. For the treatment of neurologically induced movement disorders, Merz developed Xeomin, the first botulinum toxin that is free of complex proteins.
With its tetesept and Merz Spezial brands, Merz Consumer Care is the leading provider of OTC medication, dietary supplements and skincare products in the German-speaking countries.
The Merz Pharma Group employs 2,754 people worldwide. The Company generated revenue of EUR 1,157.0 million in fiscal year 2014/15 (previous year: EUR 994.0 million).
Photos
Download File:
20160302_PR_Frankenberger_e [25 KB]
Press Contact
Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone:+49 151 42 49 1466 (DE Mobile/ Preferred)
Email: mariana.smith@merz.com